BN Business News
Add your company to Business Communicator →

Zdrowie i gospodarka · 8.10.2014

Prescription Drug User Fee Act Patient-Focused Drug Development; Request for Comments

The Food and Drug Administration (FDA) is announcing an opportunity for public comment related to FDA's patient-focused drug development initiative. This initiative is being conducted to fulfill FDA performance commitments made as part of the fifth authorization of the Prescription Drug User Fee Act (PDUFA V). This effort provides for a more systematic approach under PDUFA V for obtaining the patient perspective on disease severity and currently available treatments for a set of disease areas. FDA is publishing a preliminary list of nominated disease areas for consideration in patient-focused drug development meetings during fiscal years (FYs) 2016-2017. The public is invited to comment on this preliminary list through a public docket.

Source: Federal Register — Food and Drug AdministrationOpen original release →